Arrowhead Pharmaceuticals Reports Fiscal 2022 Third Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Arrowhead Pharmaceuticals Inc. (ARWR) Misses Q3 EPS by 11c
August 4, 2022 4:01 PM EDTArrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q3 EPS of ($0.68), $0.11 worse than the analyst estimate of ($0.57). Revenue for the quarter came in at $32.41 million versus the consensus estimate of $49.23 million.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.
... More